Literature DB >> 3363012

Concentration and distribution of thioridazine and metabolites in schizophrenic post-mortem brain tissue.

C N Svendsen1, C C Hrbek, M Casendino, R D Nichols, E D Bird.   

Abstract

Thioridazine (THD) and its major metabolites, mesoridazine (MES), sulforidazine (SULF), and northioridazine (norTHD) accumulate at a predictable rate in human brain tissue after chronic medication. Although the concentration of THD is normally lower than or the same as its major metabolite, MES, in the plasma, it was found to be up to five times as concentrated in the brain tissue of treated patients. THD and its metabolites were evenly distributed throughout all regions of the brain in chronically medicated patients. Brain concentrations of THD were also compared with those of chlorpromazine (CPZ) when both drugs had been given at the same dose before death, and were shown to be up to 10 times more concentrated in brain at doses greater than 300 mg/day. Because some of the metabolites of THD are pharmacologically active, it is important to know how they accumulate in the brain in relation to the parent compound to understand how this drug mediates its clinical effect.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3363012     DOI: 10.1016/0165-1781(88)90029-7

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.

Authors:  I Loryan; E Melander; M Svensson; M Payan; F König; B Jansson; M Hammarlund-Udenaes
Journal:  Mol Psychiatry       Date:  2016-01-26       Impact factor: 15.992

2.  Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model.

Authors:  Arnaud Tonnelier; Sandra Coecke; José-Manuel Zaldívar
Journal:  Arch Toxicol       Date:  2011-11-17       Impact factor: 5.153

3.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.

Authors:  C Korth; B C May; F E Cohen; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

Review 4.  In vitro, in vivo and in silico models of drug distribution into the brain.

Authors:  Scott G Summerfield; Kelly C Dong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-13       Impact factor: 2.745

5.  EAG2 potassium channel with evolutionarily conserved function as a brain tumor target.

Authors:  Xi Huang; Ye He; Adrian M Dubuc; Rintaro Hashizume; Wei Zhang; Jüri Reimand; Huanghe Yang; Tongfei A Wang; Samantha J Stehbens; Susan Younger; Suzanne Barshow; Sijun Zhu; Michael K Cooper; John Peacock; Vijay Ramaswamy; Livia Garzia; Xiaochong Wu; Marc Remke; Craig M Forester; Charles C Kim; William A Weiss; C David James; Marc A Shuman; Gary D Bader; Sabine Mueller; Michael D Taylor; Yuh Nung Jan; Lily Yeh Jan
Journal:  Nat Neurosci       Date:  2015-08-10       Impact factor: 24.884

6.  Inhibition of Fatty Acid Oxidation as a New Target To Treat Primary Amoebic Meningoencephalitis.

Authors:  Maarten J Sarink; Aloysius G M Tielens; Annelies Verbon; Robert Sutak; Jaap J van Hellemond
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.